The MarketReader Minute
💊 Summit Therapeutics Surges on Analyst Upgrade, While Humacyte Drops Amid Dilution Concerns and Amgen Faces Mixed Drug Trial Results | Biotech Sector Insights
Amgen (AMGN), which dropped significantly following its approval for TEPEZZA in Japan, despite positive trial results for other treatments. Regeneron (REGN) faced challenges after a legal ruling favoring Amgen, although analysts remain optimistic about its market share growth.